ArticleVaccine2022
Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination.
Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review.Journal of medical virology · 2022Pooled it
- Immunosenescence and cytomegalovirus-associated immune signatures on severe acute respiratory syndrome coronavirus 2 booster responses.The journals of gerontology. Series A, Biological sciences and medical sciences · 2026Article
- Serum per- and polyfluoroalkyl substances (PFAS) concentrations and anti-spike SARS-CoV-2 IgG levels following COVID-19 vaccination: A cross-sectional study in three communities with elevated PFAS exposure.International journal of hygiene and environmental health · 2026Article
- Estimating the Optimal COVID-19 Booster Timing Using Surrogate Correlates of Protection: A Longitudinal Antibody Study in Naïve and Previously Infected Individuals.Pathogens (Basel, Switzerland) · 2025Article
- Detection of SARS-CoV-2 RNA and Biomarkers in Device-Captured Droplets From the Lung.CHEST pulmonary · 2025Article
- ARNAX is an ideal adjuvant for COVID-19 vaccines to enhance antigen-specific CD4Journal of virology · 2025Article
- Humoral and Cell-Mediated Immunity Against SARS-CoV-2 in Healthcare Personnel Who Received Multiple mRNA Vaccines: A 4-Year Observational Study.Infectious disease reports · 2025Article
- Immune and hematologicak responses to the third dose of an mRNA COVID-19 vaccine: a six-month longitudinal study.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects.Human vaccines & immunotherapeutics · 2023Article
- Cellular immunity reflects the persistent symptoms among COVID-19 recovered patients in Japan.Scientific reports · 2023Article
- Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination.Scientific reports · 2023Article
- A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma.International journal of hematology · 2023Article
- Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine.Signal transduction and targeted therapy · 2023Article
- Durability of humoral and cell-mediated immune response after SARS-CoV-2 mRNA vaccine administration.Journal of medical virology · 2023Article
- Prediction models for neutralization activity against emerging SARS-CoV-2 variants: A cross-sectional study.Frontiers in microbiology · 2023Article
- Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections.Frontiers in immunology · 2023Article
- Article
- SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.Seminars in hematology · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate vaccine-induced humoral and cell-mediated immunity at 6 months after completion of two doses of BNT162b2 vaccination, immunoglobulin G against SARS-CoV-2 spike protein (SP IgG), 50% neutralizing antibody (NT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.